Locust Walk Insights
LOCUST WALK INSIGHTS
My (National Lampoon’s) European Vacation
I recently returned from a month in Europe as part of our effort to expand Locust Walk's European practice. It was an amazing trip meeting great people and learning valuable lessons. While I did not visit all countries for business, I thought I'd share a...
Financing overhang or hangover: The impact on partnerships for public biotech companies
Overview Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including, but not limited to, advancement of the asset(s) in...
Q2 2019 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2019 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...
Q2 2019: Global Trends in Medtech Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal...
Brian Coleman of Locust Walk to Moderate Panel at BioEquity Europe: Drawing Your Financing Roadmap
Brian Coleman, Locust Walk's Managing Director, Global Head of Financing and Sales will be moderating the panel, Drawing Your Financing Roadmap, at BioEquity Europe: Faced with an expanding range of financing options, early stage biotech executives must figure out how...
Global Business Reports Interview with Geoff Meyerson, CEO & Co-Founder of Locust Walk
Special Report on the U.S. Biopharmaceuticals Industry 2019Selected quotes from the interview with Geoff Meyerson, CEO and Co-Founder of Locust WalkLarge pharma is veering towards bolt-on acquisition deals. How is this impacting the transactions you are...
Greed is Bad: Why Defendable Commercial Assessments are Better Than Pie in the Sky
Clear, data-based financial assumptions are essential to driving a successful deal process. In a previous post, The Value of a Commercial Assessment in Supporting a Transaction, I discussed the main ways that a well-done commercial assessment...
Q1 2019: Global Trends in Medtech Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal...
Q1 2019 Report: Global Trends in Biopharma Transactions
In this report you can find an overview and analysis of the following across the biopharma market in the US, Europe, and Asia (China and Japan). Key performance indicators for the life science market IPO and private financing activity and performance Deal activity...
The Art of the Multi-Track Deal Whitepaper
Pursuing multiple deal options in parallel, known as a multi-track process, can create competitive tension that will enable a company to obtain the most value out of the deal, whether the result of that process is an asset sale, global or regional partnership, a new...
Make No Bones About It – AAOS 2019 Was All About M&A and Promising New Technology
It is that time of year again when the orthopedics community comes together to reflect on the recent American Academy of Orthopedic Surgeons (AAOS) meeting which took place in Las Vegas and finished late last week. We take pause to remember that AAOS is...
The Asia Factor Whitepaper
How Does a Smart Deal Maker "Play" This Region and Optimize the Capital Raising and Strategic Deal Making Opportunities? Authors: Hayato Watanabe, SVP, Head of Asia Koji Hirabata, Associate Stefanie Gan, Analyst Although their biopharma ecosystem dynamics are markedly...
Trends in Venture Deal Term Sheets: Favorable Climate for Founders
If you are raising capital now, the path you are about to embark on can be stressful and littered with obstacles, but the light at the end of the tunnel is worth the trials and tribulations. Despite the inherent challenges of fundraising, the current climate is quite...
2018 Annual Trends in Medtech Transactions Report
Locust Walk is a global life sciences transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...
2018 Annual Trends in Biopharma Transactions Report
Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...